Management of Persistent Low-Level Viremia in HIV
Rationale for Supplement Discontinuation
- The International Antiviral Society-USA (IAS-USA) guidelines recommend reviewing the complete medication list, including nonprescribed supplements, to ensure that drug-drug interactions are not compromising therapeutic efficacy in patients with persistent low-level viremia 1, 2
- Supplements containing multivalent cations can impair InSTI absorption, and many herbal supplements contain minerals or affect drug metabolism, making supplement removal a high-yield intervention 3
Diagnostic Considerations
- The IAS-USA guidelines define virologic failure as confirmed HIV RNA >200 copies/mL, and resistance testing is not indicated at viral load levels below this threshold 1, 2, 4
- Genotypic resistance testing has poor amplification success at HIV RNA levels below 500-1000 copies/mL 1, 2, 6
Treatment Considerations
- The IAS-USA guidelines provide Level AIa evidence that patients with low-level viremia and confirmed adherence are unlikely to benefit from ART intensification, and such changes are not recommended for patients on high-barrier regimens like bictegravir 3, 5
- Adding darunavir/cobicistat increases pill burden and potential drug-drug interactions, and cobicistat can affect renal function parameters, particularly concerning in patients with existing chronic kidney disease (CKD) 3
Follow-Up Algorithm
- The IAS-USA guidelines recommend rechecking HIV RNA in 4 weeks after stopping supplements to assess response to supplement discontinuation 1, 2, 4
- If viremia persists <200 copies/mL, continue current ART with close monitoring every 3 months 3, 7
- If HIV RNA rises to >200 copies/mL on two consecutive measurements, order resistance testing (both reverse transcriptase and integrase) 1, 2, 3, 7